Investigating a new treatment for Jansen's Disease using PTH inverse agonists
PTH Inverse Agonists as Therapy for Jansens Disease
This study is looking at a special receptor that helps with bone growth and aims to find new treatments for people with Jansen's Metaphyseal Chondrodysplasia, a condition that causes serious bone deformities, by testing how certain medications can help fix problems caused by mutations in this receptor.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10980761 on NIH RePORTER |
What this research studies
This research focuses on the PTH/PTHrP receptor, which is crucial for bone growth and mineral ion balance. It aims to explore how PTH inverse agonists can suppress abnormal signaling caused by mutations in this receptor, specifically in patients with Jansen's Metaphyseal Chondrodysplasia. By understanding the receptor's role and testing new therapeutic approaches, the research seeks to improve outcomes for patients suffering from severe bone deformities and related complications. The study involves laboratory experiments to assess the effectiveness of these treatments on cellular models of the disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with Jansen's Metaphyseal Chondrodysplasia or Eiken Syndrome who have specific mutations in the PTH1R gene.
Not a fit: Patients with other forms of bone diseases not related to PTH1R mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel therapy that alleviates severe bone deformities and improves quality of life for patients with Jansen's Disease.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other bone-related conditions, indicating potential for success in this novel approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Jueppner, Harald W. — Massachusetts General Hospital
- Study coordinator: Jueppner, Harald W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.